Clinical Competition Candidate
NAMENDA XR
NAMENDA XR carries use-code patent, low complexity (1/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 39 months away. Active clinical competition may compress the generic entry window.
LOE window
39months
to latest listed patent expiry (September 24, 2029)
Expiry attractiveness: 4/5
Patent profile
Substance patent (none)
Product / formulation patent (none)
Use-code patent (listed)
Patent count: 2
Complexity score: 1/5
Clinical competition
Score: 5/5
Active trials linked: 303
Phase 2/3 trials: 145
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: MEMANTINE HYDROCHLORIDE
Applicant (NDA holder): ABBVIE INC
Confidence: High